(Q36589861)

15 August 2017

1 reference

title

Autologous renal cell cancer vaccines using heat shock protein-peptide complexes (English)

1 reference

15 August 2017

Maryam Aalamian

1

1 reference

15 August 2017

Ephraim Fuchs

series ordinal

2

1 reference

15 August 2017

Renu Gupta

series ordinal

3

1 reference

15 August 2017

Daniel L Levey

series ordinal

4

1 reference

15 August 2017

publication date

1 September 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

24

1 reference

15 August 2017

issue

5

1 reference

15 August 2017

page(s)

425-433

1 reference

Tumor rejection antigens of chemically induced sarcomas of inbred mice

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Immunotherapy using heat-shock protein preparations of leukemia cells after syngeneic bone marrow transplantation in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Biochemical, cell biological and immunological issues surrounding the endoplasmic reticulum chaperone GRP94/gp96.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

5'-structural analysis of genes encoding polymorphic antigens of chemically induced tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Structural analysis of substrate binding by the molecular chaperone DnaK

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

HSP70 peptide binding mutants separate antigen delivery from dendritic cell stimulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Identification of the N-terminal peptide binding site of glucose-regulated protein 94.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Generation of murine CTL by a hepatitis B virus-specific peptide and evaluation of the adjuvant effect of heat shock protein glycoprotein 96 and its terminal fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Testing the role of gp96 as peptide chaperone in antigen processing.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Cellular requirements for tumor-specific immunity elicited by heat shock proteins: tumor rejection antigen gp96 primes CD8+ T cells in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Essential role of CD91 in re-presentation of gp96-chaperoned peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Bacterial heat shock proteins promote CD91-dependent class I MHC cross-presentation of chaperoned peptide to CD8+ T cells by cytosolic mechanisms in dendritic cells versus vacuolar mechanisms in macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Low density lipoprotein receptor-related protein is a calreticulin coreceptor that signals focal adhesion disassembly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Human platelets express heat shock protein receptors and regulate dendritic cell maturation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Expression of the common heat-shock protein receptor CD91 is increased on monocytes of exposed yet HIV-1-seronegative subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

The common heat shock protein receptor CD91 is up-regulated on monocytes of advanced melanoma slow progressors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Disease-associated dendritic cells respond to disease-specific antigens through the common heat shock protein receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

The heat-shock protein receptor CD91 is up-regulated in monocytes of HIV-1-infected "true" long-term nonprogressors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

The receptor for heat shock protein 60 on macrophages is saturable, specific, and distinct from receptors for other heat shock proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Glycoprotein 96 can chaperone both MHC class I- and class II-restricted epitopes for in vivo presentation, but selectively primes CD8+ T cell effector function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Vaccination with heat shock protein-peptide complexes: from basic science to clinical applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Tumor-derived heat shock protein 70 peptide complexes are cross-presented by human dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Peripheral blood mononuclear cell proliferation to heat shock protein-70 derived from autologous lung carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

The heat shock protein gp96 induces maturation of dendritic cells and down-regulation of its receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Heat shock proteins generate beta-chemokines which function as innate adjuvants enhancing adaptive immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Heat shock proteins gp96 and hsp70 activate the release of nitric oxide by APCs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Cutting edge: heat shock protein (HSP) 60 activates the innate immune response: CD14 is an essential receptor for HSP60 activation of mononuclear cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Primary tumor tissue lysates are enriched in heat shock proteins and induce the maturation of human dendritic cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

HSP70 stimulates cytokine production through a CD14-dependant pathway, demonstrating its dual role as a chaperone and cytokine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Cutting edge: heat shock protein gp96 induces maturation and migration of CD11c+ cells in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Immunotherapy of human cancer: lessons from mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1+2- suppressor T cells down-regulate the generation of Ly-1-2+ effector T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Mechanisms and functional significance of tumour-induced dendritic-cell defects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Spontaneous regression of brain metastasis secondary to renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

An alternative open reading frame of the human macrophage colony-stimulating factor gene is independently translated and codes for an antigenic peptide of 14 amino acids recognized by tumor-infiltrating CD8 T lymphocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Flow cytometric analysis of tumour-infiltrating lymphocytes in patients with renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Immunotherapy of metastatic renal cell cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Phase II study of subcutaneous interleukin-2 in unselected patients with advanced renal cell cancer on an outpatient basis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Natural killer cells in antiviral defense: function and regulation by innate cytokines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Adjuvant interferon-alpha in malignant melanoma: current status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Interleukin-2, interferon-alpha and 5-fluorouracil immunotherapy for metastatic renal cell carcinoma: the all Ireland experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

IL-2 in combination with IFN- alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Nephrectomy and interleukin-2 for metastatic renal-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Dendritic cell-tumor cell hybrid vaccination for metastatic cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a phase I/II study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Allogeneic stem cell transplantation for renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Heat shock protein vaccines against cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2005.08.009

Immunotherapy for advanced renal cell cancer

7 January 2021

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD001425.PUB2

Identifiers

DOI

10.1016/J.UROLONC.2005.08.009

1 reference

15 August 2017

1 reference